


## Encenicline hydrochloride

<b>Cat. No.:</b>	HY-15430A
<b>CAS No.:</b>	550999-74-1
<b>Molecular Formula:</b>	C <sub>16</sub> H <sub>18</sub> Cl <sub>2</sub> N <sub>2</sub> OS
<b>Molecular Weight:</b>	357.3
<b>Target:</b>	nAChR
<b>Pathway:</b>	Membrane Transporter/Ion Channel; Neuronal Signaling
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



H-Cl

### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : ≥ 50 mg/mL (139.94 mM)					
	* "≥" means soluble, but saturation unknown.					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
		<b>1 mM</b>		2.7988 mL	13.9938 mL	27.9877 mL
<b>5 mM</b>			0.5598 mL	2.7988 mL	5.5975 mL	
	<b>10 mM</b>		0.2799 mL	1.3994 mL	2.7988 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.00 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (7.00 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (7.00 mM); Clear solution					

### BIOLOGICAL ACTIVITY

<b>Description</b>	Encenicline hydrochloride (EVP-6124 hydrochloride) is a novel partial agonist of α7 neuronal nicotinic acetylcholine receptors (nAChRs).
<b>IC<sub>50</sub> &amp; Target</b>	α7 nAChR <sup>[1]</sup>
<b>In Vitro</b>	Encenicline (EVP-6124) displaces [ <sup>3</sup> H]-MLA (Methyllycaconitine) (K <sub>i</sub> =9.98 nM, pIC <sub>50</sub> =7.65±0.06, n=3) and [ <sup>125</sup> I]-α-bungarotoxin (K <sub>i</sub> =4.33 nM, pIC <sub>50</sub> =8.07±0.04, n=3). Encenicline (EVP-6124) is approximately 300 fold more potent than the natural agonist ACh (K <sub>i</sub> =3 μM), measured in binding assays using [ <sup>3</sup> H]-MLA. Encenicline hydrochloride inhibits the 5-HT <sub>3</sub> receptor by 51% at

10 nM, the lowest concentration tested. Evaluation of the human 5-HT<sub>2B</sub> receptor expressed in CHO cells demonstrates displacement of [<sup>3</sup>H]-mesulergine (K<sub>i</sub>=14 nM) and only antagonist activity in the rat gastric fundus assay at an IC<sub>50</sub> of 16 μM. In binding and functional experiments, Encenicline (EVP-6124) shows selectivity for α7 nAChRs and does not activate or inhibit heteromeric α4β2 nAChRs<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

Encenicline hydrochloride has good brain penetration and an adequate exposure time. Encenicline hydrochloride (0.3 mg/kg, p.o.) significantly restores memory function in scopolamine-treated rats (0.1 mg/kg, i.p.) in an object recognition task (ORT). Although donepezil at 0.1 mg/kg, p.o. or Encenicline hydrochloride at 0.03 mg/kg, p.o. did not improve memory in this task, co-administration of these sub-efficacious doses fully restored memory. In a natural forgetting test, an ORT with a 24 h retention time, Encenicline hydrochloride improved memory at 0.3 mg/kg, p.o. This improvement is blocked by the selective α7 nAChR antagonist methyllycaconitine (0.3 mg/kg, i.p. or 10 μg, i.c.v.). Encenicline hydrochloride is found to bind moderately to rat plasma proteins with a mean fu of 0.11±0.01 (mean±SD) or 11%. Over a range of 0.1-30 mg/kg, p.o., Encenicline hydrochloride demonstrates proportional dose escalation. T<sub>max</sub> is at 4 h in plasma and 2 h brain, although the brain concentrations remained similar between 2 and 8 h. The B:P ratios are 1.7-5.1 between 1 and 8 h<sup>[1]</sup>. Pharmacokinetic studies have shown that Encenicline hydrochloride (0.4 mg/kg, i.p.) reaches peak brain concentration 2 hr after administration and remains at effective concentrations for at least 4 hr. Encenicline hydrochloride is administered to WT mice at ZT0 (0.4 mg/kg i.p single dose) and significantly increases the saturation index of NMDARs in slices obtained 4 hr later without causing prolonged wakefulness or enhanced locomotor activity<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

#### Animal Administration<sup>[1][2]</sup>

##### Rats<sup>[1]</sup>

Twenty-four 2.5-month-old male Wistar rats (average body weight: 329 g) are used. Before testing EVP-6124, the effects of scopolamine alone at 0.03, 0.1, or 0.3 mg/kg, i.p. in the ORT are determined (n=8 per treatment). Scopolamine (0.1 mg/kg, i.p.) injected 30 min before T1 resulted in a robust deficit at T2 when a 1 h interval is used. The d2 index is not significantly different from the chance level of performance; and there are no changes in exploratory behavior for 0.1 mg/kg, i.p. of scopolamine compared with saline. Subsequently, the ability of Encenicline (EVP-6124) to reverse the memory impairment induced by 0.1 mg/kg of scopolamine is tested. First, scopolamine and then Encenicline (EVP-6124) (0.03, 0.1, 0.3, and 1.0 mg/kg, p.o.) are administered 30 min before T1. For the control treatments, animals received either deionized water (p.o.) plus saline (i.p.) or deionized water (p.o.) plus 0.1 mg/kg scopolamine (i.p.).

##### Mice<sup>[2]</sup>

Adult male mice (3-6 months old) are used throughout this study. Encenicline (EVP-6124) is injected i.p. (0.4 mg/kg) at Zeitgeber time (ZT0) in awake mice (9 mice total for this experiment), in the animal facility. Mice are then immediately returned to their home cage with their siblings and left undisturbed for 4 hr (ZT4). During this time, they are closely monitored to check for possible behavioral effects of Encenicline (EVP-6124) injection. All of the 9 injected mice nested and are immobile in the hour following the injection.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Neuron. 2017 May 17;94(4):840-854.e7.
- Eur J Pharmacol. 2017 Sep 15;811:110-116.
- Psychopharmacology (Berl). 2019 Apr;236(4):1245-1253.
- Faculty of Health Sciences. 2020 Oct.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

---

## REFERENCES

- [1]. Prickaerts J, et al. EVP-6124, a novel and selective  $\alpha 7$  nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of  $\alpha 7$  nicotinic acetylcholine receptors. *Neuropharmacology*. 2012 Feb;62(2):109
- [2]. Thomas Papouin, et al. Septal Cholinergic Neuromodulation Tunes the Astrocyte-Dependent Gating of Hippocampal NMDA Receptors to Wakefulness. *Neuron*. 2017 May 17;94:1-15.
- [3]. Papouin T, et al. Septal Cholinergic Neuromodulation Tunes the Astrocyte-Dependent Gating of Hippocampal NMDA Receptors to Wakefulness. *Neuron*. 2017 May 17;94(4):840-854.e7.
- [4]. Maehara S, et al. Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 2A inhibitor, PDM-631. *Eur J Pharmacol*. 2017 Sep 15;811:110-116.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA